Thalia Therapeutics Featured in Fierce biotech

This Fierce Biotech article highlights the exciting potential of RNA-based gene silencing therapies to treat previously "undruggable" targets—particularly a serious cardiovascular risk factor called Lp(a), which is prevalent at dangerous levels in up to 20% of the population. Lp(a) levels are determined genetically at birth and do not reduce with exercise, diet, or weight loss; high levels are correlated with a significantly increased risk of cardiovascular events.

At Thalia Therapeutics, we are focused on addressing this unmet need with a dual-acting siRNA approach designed to inhibit both Lp(a) and PCSK9, two independent cardiovascular targets.

CEO David Solomon commented: “The dual-acting medicine is a really strong approach,” highlighting the growing momentum behind combination therapies to drive greater efficacy in complex diseases.

As the science matures, companies targeting high-value indications like cardiovascular disease with differentiated, platform-driven approaches stand to capture significant value.

Read the full article here: Fierce Biotech: Biotech’s next gold rush

Feel free to engage and ask questions to the Thalia Therapeutics team below.